Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow

Gui Lin Zhan, Carol B Toris, Carl B. Camras, Yun Liang Wang, Michael E. Yablonski

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The mechanism of the ocular hypotensive effect of bunazosin hydrochloride (an α1-adrenergic antagonist) and the possible intermediary role of prostaglandins were studied in New Zealand albino rabbits. Aqueous flow, outflow facility and uveoscleral outflow were determined by fluorophotometry, and intraocular pressure (IOP) was measured by pneumatonometry on the fourth day of twice daily topical treatment with 0.1% bunazosin. Uveoscleral outflow was measured with a tracer infusion technique at 1 to 2 hours after one dose of 0.1% bunazosin. Total outflow facility was measured by a two-level constant-pressure infusion method before and at one hour after one dose of 0.1% bunazosin. The effect of topically applied cyclooxygenase inhibitors, including 0.25% indomethacin and 0.03% flurbiprofen, on the IOP reduction after bunazosin was evaluated. At 3 hours after the seventh consecutive dose given twice-daily, bunazosin significantly (P<0.001) reduced IOP to 13.4 ± 0.8 mm Hg (mean ± SEM) from a baseline of 19.6 ± 1.1 mm Hg. Indomethacin significantly inhibited the IOP reduction after one dose of bunazosin, whereas flurbiprofen did not (repeated measures ANOVA). Bunazosin significantly increased uveoscleral outflow (P<0.05) and total outflow facility (P<0.02), but not fluorophotometric outflow facility or aqueous flow. It is concluded that, in rabbits, 0.1% bunazosin reduces lOP predominantly by increasing uveoscleral outflow. The role of prostaglandins in this effect is equivocal.

Original languageEnglish (US)
Pages (from-to)217-228
Number of pages12
JournalJournal of Ocular Pharmacology and Therapeutics
Volume14
Issue number3
DOIs
StatePublished - Jun 1998

Fingerprint

Intraocular Pressure
Rabbits
Flurbiprofen
Indomethacin
Prostaglandins
Fluorophotometry
bunazosin
Adrenergic Antagonists
Cyclooxygenase Inhibitors
Analysis of Variance
Pressure

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow. / Zhan, Gui Lin; Toris, Carol B; Camras, Carl B.; Wang, Yun Liang; Yablonski, Michael E.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 14, No. 3, 06.1998, p. 217-228.

Research output: Contribution to journalArticle

Zhan, Gui Lin ; Toris, Carol B ; Camras, Carl B. ; Wang, Yun Liang ; Yablonski, Michael E. / Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow. In: Journal of Ocular Pharmacology and Therapeutics. 1998 ; Vol. 14, No. 3. pp. 217-228.
@article{2464621b42a54d859631ec71fefe3e68,
title = "Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow",
abstract = "The mechanism of the ocular hypotensive effect of bunazosin hydrochloride (an α1-adrenergic antagonist) and the possible intermediary role of prostaglandins were studied in New Zealand albino rabbits. Aqueous flow, outflow facility and uveoscleral outflow were determined by fluorophotometry, and intraocular pressure (IOP) was measured by pneumatonometry on the fourth day of twice daily topical treatment with 0.1{\%} bunazosin. Uveoscleral outflow was measured with a tracer infusion technique at 1 to 2 hours after one dose of 0.1{\%} bunazosin. Total outflow facility was measured by a two-level constant-pressure infusion method before and at one hour after one dose of 0.1{\%} bunazosin. The effect of topically applied cyclooxygenase inhibitors, including 0.25{\%} indomethacin and 0.03{\%} flurbiprofen, on the IOP reduction after bunazosin was evaluated. At 3 hours after the seventh consecutive dose given twice-daily, bunazosin significantly (P<0.001) reduced IOP to 13.4 ± 0.8 mm Hg (mean ± SEM) from a baseline of 19.6 ± 1.1 mm Hg. Indomethacin significantly inhibited the IOP reduction after one dose of bunazosin, whereas flurbiprofen did not (repeated measures ANOVA). Bunazosin significantly increased uveoscleral outflow (P<0.05) and total outflow facility (P<0.02), but not fluorophotometric outflow facility or aqueous flow. It is concluded that, in rabbits, 0.1{\%} bunazosin reduces lOP predominantly by increasing uveoscleral outflow. The role of prostaglandins in this effect is equivocal.",
author = "Zhan, {Gui Lin} and Toris, {Carol B} and Camras, {Carl B.} and Wang, {Yun Liang} and Yablonski, {Michael E.}",
year = "1998",
month = "6",
doi = "10.1089/jop.1998.14.217",
language = "English (US)",
volume = "14",
pages = "217--228",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow

AU - Zhan, Gui Lin

AU - Toris, Carol B

AU - Camras, Carl B.

AU - Wang, Yun Liang

AU - Yablonski, Michael E.

PY - 1998/6

Y1 - 1998/6

N2 - The mechanism of the ocular hypotensive effect of bunazosin hydrochloride (an α1-adrenergic antagonist) and the possible intermediary role of prostaglandins were studied in New Zealand albino rabbits. Aqueous flow, outflow facility and uveoscleral outflow were determined by fluorophotometry, and intraocular pressure (IOP) was measured by pneumatonometry on the fourth day of twice daily topical treatment with 0.1% bunazosin. Uveoscleral outflow was measured with a tracer infusion technique at 1 to 2 hours after one dose of 0.1% bunazosin. Total outflow facility was measured by a two-level constant-pressure infusion method before and at one hour after one dose of 0.1% bunazosin. The effect of topically applied cyclooxygenase inhibitors, including 0.25% indomethacin and 0.03% flurbiprofen, on the IOP reduction after bunazosin was evaluated. At 3 hours after the seventh consecutive dose given twice-daily, bunazosin significantly (P<0.001) reduced IOP to 13.4 ± 0.8 mm Hg (mean ± SEM) from a baseline of 19.6 ± 1.1 mm Hg. Indomethacin significantly inhibited the IOP reduction after one dose of bunazosin, whereas flurbiprofen did not (repeated measures ANOVA). Bunazosin significantly increased uveoscleral outflow (P<0.05) and total outflow facility (P<0.02), but not fluorophotometric outflow facility or aqueous flow. It is concluded that, in rabbits, 0.1% bunazosin reduces lOP predominantly by increasing uveoscleral outflow. The role of prostaglandins in this effect is equivocal.

AB - The mechanism of the ocular hypotensive effect of bunazosin hydrochloride (an α1-adrenergic antagonist) and the possible intermediary role of prostaglandins were studied in New Zealand albino rabbits. Aqueous flow, outflow facility and uveoscleral outflow were determined by fluorophotometry, and intraocular pressure (IOP) was measured by pneumatonometry on the fourth day of twice daily topical treatment with 0.1% bunazosin. Uveoscleral outflow was measured with a tracer infusion technique at 1 to 2 hours after one dose of 0.1% bunazosin. Total outflow facility was measured by a two-level constant-pressure infusion method before and at one hour after one dose of 0.1% bunazosin. The effect of topically applied cyclooxygenase inhibitors, including 0.25% indomethacin and 0.03% flurbiprofen, on the IOP reduction after bunazosin was evaluated. At 3 hours after the seventh consecutive dose given twice-daily, bunazosin significantly (P<0.001) reduced IOP to 13.4 ± 0.8 mm Hg (mean ± SEM) from a baseline of 19.6 ± 1.1 mm Hg. Indomethacin significantly inhibited the IOP reduction after one dose of bunazosin, whereas flurbiprofen did not (repeated measures ANOVA). Bunazosin significantly increased uveoscleral outflow (P<0.05) and total outflow facility (P<0.02), but not fluorophotometric outflow facility or aqueous flow. It is concluded that, in rabbits, 0.1% bunazosin reduces lOP predominantly by increasing uveoscleral outflow. The role of prostaglandins in this effect is equivocal.

UR - http://www.scopus.com/inward/record.url?scp=0031861984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031861984&partnerID=8YFLogxK

U2 - 10.1089/jop.1998.14.217

DO - 10.1089/jop.1998.14.217

M3 - Article

C2 - 9671429

AN - SCOPUS:0031861984

VL - 14

SP - 217

EP - 228

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 3

ER -